Nanobiotix (NASDAQ:NBTX) Stock Price Up 9% – Here’s What Happened

Posted by Francis Steltz on May 13th, 2026

Shares of Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX – Get Free Report) rose 9% during trading on Wednesday . The company traded as high as $52.68 and last traded at $52.5870. Approximately 25,017 shares changed hands during trading, a decline of 57% from the average daily volume of 58,466 shares. The stock had previously closed at $48.24.

Analyst Upgrades and Downgrades

NBTX has been the subject of several analyst reports. Guggenheim raised their price target on shares of Nanobiotix from $26.00 to $36.00 and gave the company a “buy” rating in a research note on Thursday, April 2nd. UBS Group raised their price target on shares of Nanobiotix from $3.50 to $30.00 and gave the company a “neutral” rating in a research note on Friday, May 1st. Weiss Ratings reissued a “sell (d-)” rating on shares of Nanobiotix in a research note on Tuesday, April 21st. Finally, TD Cowen reissued a “buy” rating on shares of Nanobiotix in a research note on Thursday, March 12th. Four equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $26.67.

Get Our Latest Research Report on NBTX

Nanobiotix Price Performance

The business has a 50 day moving average price of $33.83 and a 200-day moving average price of $26.08.

Nanobiotix (NASDAQ:NBTX – Get Free Report) last announced its quarterly earnings data on Sunday, February 15th. The company reported ($0.23) earnings per share (EPS) for the quarter. The firm had revenue of $3.42 million during the quarter. Sell-side analysts predict that Nanobiotix S.A. – Sponsored ADR will post 0.53 earnings per share for the current fiscal year.

Institutional Trading of Nanobiotix

Several hedge funds have recently modified their holdings of NBTX. Royal Bank of Canada grew its stake in shares of Nanobiotix by 2,000.0% in the 4th quarter. Royal Bank of Canada now owns 2,625 shares of the company’s stock valued at $61,000 after buying an additional 2,500 shares during the period. Optiver Holding B.V. acquired a new stake in shares of Nanobiotix in the 3rd quarter valued at about $101,000. Marshall Wace LLP acquired a new stake in shares of Nanobiotix in the 4th quarter valued at about $220,000. Finally, Millennium Management LLC acquired a new stake in shares of Nanobiotix in the 4th quarter valued at about $390,000. Institutional investors own 38.81% of the company’s stock.

Nanobiotix Company Profile

(Get Free Report)

Nanobiotix is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the development of novel nanopharmaceuticals to improve cancer treatment. The company’s lead product, NBTXR3, is a first-in-class radioenhancer composed of hafnium oxide nanoparticles designed to amplify the effect of radiotherapy on tumor cells while sparing surrounding healthy tissue. Nanobiotix has established clinical programs across multiple cancer indications, including soft tissue sarcoma, head and neck cancer, and hepatocellular carcinoma.

Since its inception, Nanobiotix has advanced NBTXR3 through pivotal trials and secured CE Mark approval in Europe for the treatment of soft tissue sarcoma.